SG11202106765XA - Anti-pd-1 binding proteins and methods of use thereof - Google Patents

Anti-pd-1 binding proteins and methods of use thereof

Info

Publication number
SG11202106765XA
SG11202106765XA SG11202106765XA SG11202106765XA SG11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA SG 11202106765X A SG11202106765X A SG 11202106765XA
Authority
SG
Singapore
Prior art keywords
methods
binding proteins
proteins
binding
Prior art date
Application number
SG11202106765XA
Inventor
David Johnson
Adam Adler
Rena Mizrahi
Yoong Lim
Michael Asensio
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of SG11202106765XA publication Critical patent/SG11202106765XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202106765XA 2018-12-27 2019-12-27 Anti-pd-1 binding proteins and methods of use thereof SG11202106765XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785660P 2018-12-27 2018-12-27
PCT/US2019/068824 WO2020140088A1 (en) 2018-12-27 2019-12-27 Anti-pd-1 binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202106765XA true SG11202106765XA (en) 2021-07-29

Family

ID=71127358

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106765XA SG11202106765XA (en) 2018-12-27 2019-12-27 Anti-pd-1 binding proteins and methods of use thereof

Country Status (12)

Country Link
US (1) US20220064302A1 (en)
EP (1) EP3902822A4 (en)
JP (1) JP2022516073A (en)
KR (1) KR20210121046A (en)
CN (1) CN113544146A (en)
AU (1) AU2019414968A1 (en)
BR (1) BR112021012667A2 (en)
CA (1) CA3124971A1 (en)
IL (1) IL284157A (en)
MX (1) MX2021007692A (en)
SG (1) SG11202106765XA (en)
WO (1) WO2020140088A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3902563A4 (en) * 2018-12-27 2022-12-28 Gigagen, Inc. Anti-pd-l1 binding proteins and methods of use thereof
US20240002534A1 (en) * 2020-11-30 2024-01-04 Merck Sharp & Dohme Llc Arginase 1 binders for inhibiting arginase 1 activity
BR112023020365A2 (en) * 2021-04-26 2023-11-21 Millennium Pharm Inc ANTI-CLEC12A ANTIBODY OR ANTIGEN BINDING FRAGMENT, METHOD OF TREATMENT OF A CANCER, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID SEQUENCE, VECTOR, CELL, AND, METHOD OF TREATMENT OF CANCER
EP4352106A1 (en) * 2021-06-11 2024-04-17 Memorial Sloan-Kettering Cancer Center Anti-upar antibodies and uses thereof
AU2022337142A1 (en) * 2021-09-02 2024-03-07 Memorial Hospital For Cancer And Allied Diseases Anti-dll3 antibodies and uses thereof
WO2024044732A2 (en) * 2022-08-25 2024-02-29 Bright Biopharmaceutical Multispecific antibodies and uses thereof
WO2024050371A1 (en) * 2022-08-29 2024-03-07 Fred Hutchinson Cancer Center Antibodies with novel fc modification combinations that increase antibody function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101339628B1 (en) * 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI595006B (en) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
CN106939047B (en) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 PD-L1 antibody and preparation method thereof
WO2017124050A1 (en) * 2016-01-14 2017-07-20 Bps Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
CN105754990A (en) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody

Also Published As

Publication number Publication date
EP3902822A4 (en) 2022-12-28
JP2022516073A (en) 2022-02-24
CN113544146A (en) 2021-10-22
MX2021007692A (en) 2021-09-30
EP3902822A1 (en) 2021-11-03
IL284157A (en) 2021-08-31
BR112021012667A2 (en) 2022-01-11
WO2020140088A1 (en) 2020-07-02
CA3124971A1 (en) 2020-07-02
US20220064302A1 (en) 2022-03-03
AU2019414968A1 (en) 2021-08-12
KR20210121046A (en) 2021-10-07

Similar Documents

Publication Publication Date Title
IL281783A (en) Sirpα binding proteins and methods of use thereof
IL281683A (en) Dll3 binding proteins and methods of use
IL275782A (en) Multispecific antigen binding proteins and methods of use thereof
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL288071A (en) Epcam binding proteins and methods of use
IL261666A (en) Binding proteins and methods of use thereof
EP3635013A4 (en) Nectin-4 binding proteins and methods of use thereof
IL261432A (en) Inducible binding proteins and methods of use
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL284157A (en) Anti-pd-1 binding proteins and methods of use thereof
IL279201A (en) Multi-specific binding proteins and methods of use thereof
IL269074A (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL284156A (en) Anti-ctla-4 binding proteins and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL283231A (en) Dpep-1 binding agents and methods of use
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
IL284364A (en) Anti-pd-l1 binding proteins and methods of use thereof